PubRank

C Balotta

Author PubWeight™ 34.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995 3.15
2 Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001 2.50
3 Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998 1.35
4 Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol 1991 1.32
5 Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol 1996 1.27
6 Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996 1.23
7 Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000 1.17
8 Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors. Clin Exp Immunol 2002 1.13
9 Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol 1987 1.08
10 Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med 2010 1.05
11 Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 2000 1.01
12 Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 1996 0.99
13 Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res Hum Retroviruses 1996 0.97
14 Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS 1996 0.90
15 Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol 1990 0.86
16 Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta 1986 0.85
17 Modulation of the locomotory capacity of human large granular lymphocytes. Cell Immunol 1986 0.84
18 Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2000 0.82
19 Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy. Antivir Ther 2001 0.81
20 Clinical and immunological aspects of HIV infection in drug addicts. Clin Immunol Immunopathol 1989 0.81
21 Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 1997 0.80
22 Long-term resistance to HIV infection in vertical HIV infection: cytokine production, HIV isolation, and HIV phenotype define long-term resistant hosts. Pathobiology 1997 0.79
23 Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine. AIDS 1991 0.78
24 Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. Clin Microbiol Infect 2011 0.78
25 Virologic and immunologic markers of disease progression in pediatric HIV infection. AIDS Res Hum Retroviruses 1996 0.78
26 Persisting HIV-1 replication triggered by acute hepatitis A virus infection. Antivir Ther 2000 0.78
27 Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. Eur J Pharmacol 1989 0.77
28 Soluble HIV suppressive factors: more than one Holy Grail? Immunol Today 1996 0.77
29 Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy. AIDS 1998 0.76
30 Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Br J Haematol 1998 0.76
31 Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency. Hematol J 2001 0.76
32 CD4 count in HIV infection is positively correlated to interferon-gamma and negatively correlated to interleukin-10 in vitro production. AIDS 1996 0.76
33 Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. J Biol Regul Homeost Agents 2001 0.75
34 Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Antivir Ther 1996 0.75
35 Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. AIDS 2000 0.75
36 Overview on HIV-1-related drug resistance: from theory to clinical practice. J Biol Regul Homeost Agents 1998 0.75
37 AIDS in a long-term HIV-1-infected patient with a stable high CD4+ cell count and conserved CD4+CD45RO+ subpopulation. AIDS 1996 0.75
38 Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors. Clin Immunol Immunopathol 1997 0.75